mibefradil has been researched along with isradipine in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (40.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Bosse, E; Flockerzi, V; Hofmann, F; Lacinová, L; Ludwig, A | 1 |
| Bosse, E; Donatin, K; Flockerzi, V; Hofmann, F; Lacinova, L; Ludwig, A; Welling, A | 1 |
| Birnbaumer, L; Hofmann, F; Ito, H; Klugbauer, N; Lacinová, L; Schuster, A | 1 |
| Backman, JT; Kivistö, KT; Neuvonen, PJ; Wang, JS; Wen, X | 1 |
| Babcock, DF; Hille, B; Wennemuth, G; Westenbroek, RE; Xu, T | 1 |
| Antepohl, W; Haaf, O; Herzig, S; Huber, I; Matthes, J; Striessnig, J | 1 |
| Benquet, P; Frere, S; Pichon, Y; Tiaho, F | 1 |
1 trial(s) available for mibefradil and isradipine
| Article | Year |
|---|---|
Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam.
Topics: Administration, Oral; Adult; Anti-Anxiety Agents; Area Under Curve; Calcium Channel Blockers; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Double-Blind Method; Female; Humans; Isradipine; Male; Mibefradil; Mixed Function Oxygenases; Triazolam | 1999 |
9 other study(ies) available for mibefradil and isradipine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
The block of the expressed L-type calcium channel is modulated by the beta 3 subunit.
Topics: Animals; Benzimidazoles; Calcium Channel Blockers; Calcium Channels; Calcium Channels, L-Type; CHO Cells; Cricetinae; Feedback; Gallopamil; Gene Expression; Intracellular Membranes; Isradipine; Macromolecular Substances; Membrane Potentials; Mibefradil; Microsomes; Myocardium; Rabbits; Recombinant Proteins; Structure-Activity Relationship; Tetrahydronaphthalenes; Transfection; Verapamil | 1995 |
Expression of the L-type calcium channel with two different beta subunits and its modulation by Ro 40-5967.
Topics: Animals; Antibodies, Monoclonal; Benzimidazoles; Calcium Channel Blockers; Calcium Channels; CHO Cells; Cricetinae; Electrophysiology; Isradipine; Mibefradil; Muscle, Smooth; Stereoisomerism; Tetrahydronaphthalenes; Transfection; Verapamil | 1995 |
The IVS6 segment of the L-type calcium channel is critical for the action of dihydropyridines and phenylalkylamines.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Amino Acid Sequence; Benzimidazoles; Calcium; Calcium Channel Blockers; Calcium Channels; Calcium Channels, L-Type; Cell Line; Humans; Ion Channel Gating; Isradipine; Mibefradil; Molecular Sequence Data; Muscle Proteins; Protein Structure, Tertiary; Recombinant Fusion Proteins; Sequence Alignment; Structure-Activity Relationship; Tetrahydronaphthalenes; Transfection; Verapamil | 1996 |
CaV2.2 and CaV2.3 (N- and R-type) Ca2+ channels in depolarization-evoked entry of Ca2+ into mouse sperm.
Topics: Animals; Cadmium; Calcium; Calcium Channel Blockers; Calcium Channels, N-Type; Calcium Channels, R-Type; Calcium Signaling; Ion Channel Gating; Isradipine; Kinetics; Male; Membrane Potentials; Mibefradil; Mice; Neurotoxins; Nickel; Nitrendipine; omega-Conotoxin GVIA; omega-Conotoxins; Scorpion Venoms; Spermatozoa | 2000 |
Pharmacodynamic interaction between mibefradil and other calcium channel blockers.
Topics: Amlodipine; Animals; Arrhythmias, Cardiac; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Cell Membrane; Dihydropyridines; Drug Interactions; Ethosuximide; Female; Gallopamil; Humans; In Vitro Techniques; Isradipine; Male; Mibefradil; Myocardial Contraction; Perfusion; Radioligand Assay; Rats; Rats, Wistar; Ventricular Pressure | 2000 |
Properties and development of calcium currents in embryonic cockroach neurons.
Topics: Amiloride; Animals; Barium; Calcium; Calcium Channel Blockers; Calcium Channels; Calcium Channels, N-Type; Calcium Channels, P-Type; Calcium Channels, T-Type; Dose-Response Relationship, Drug; In Vitro Techniques; Isradipine; Membrane Potentials; Mibefradil; Neurons; omega-Agatoxin IVA; omega-Conotoxin GVIA; Patch-Clamp Techniques; Periplaneta; Verapamil | 2000 |